BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 17032501)

  • 21. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
    Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
    Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
    Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
    Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of the p53 tumor suppressor gene product in esophageal and gastric carcinomas.
    Fléjou JF; Muzeau F; Potet F; Lepelletier F; Fékété F; Hénin D
    Pathol Res Pract; 1994 Dec; 190(12):1141-8. PubMed ID: 7540752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of p53 protein in Barrett's adenocarcinoma and adenocarcinoma of the gastric cardia and antrum.
    Jovanović I; Todorović V; Milosavljević T; Micev M; Pesko P; Bjelović M; Mouzas Y; Tzardi M
    Vojnosanit Pregl; 2005 Dec; 62(12):879-85. PubMed ID: 16375215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression.
    Kuester D; Dar AA; Moskaluk CC; Krueger S; Meyer F; Hartig R; Stolte M; Malfertheiner P; Lippert H; Roessner A; El-Rifai W; Schneider-Stock R
    Neoplasia; 2007 Mar; 9(3):236-45. PubMed ID: 17401463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression profile of malignant and nonmalignant lesions of esophagus and stomach: differential activity of functional modules related to inflammation and lipid metabolism.
    Gomes LI; Esteves GH; Carvalho AF; Cristo EB; Hirata R; Martins WK; Marques SM; Camargo LP; Brentani H; Pelosof A; Zitron C; Sallum RA; Montagnini A; Soares FA; Neves EJ; Reis LF
    Cancer Res; 2005 Aug; 65(16):7127-36. PubMed ID: 16103062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer.
    Yonemura Y; Endou Y; Kimura K; Fushida S; Bandou E; Taniguchi K; Kinoshita K; Ninomiya I; Sugiyama K; Heizmann CW; Schafer BW; Sasaki T
    Clin Cancer Res; 2000 Nov; 6(11):4234-42. PubMed ID: 11106237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromosomal numerical aberrations are frequent in oesophageal and gastric adenocarcinomas: a study using in-situ hybridization.
    Beuzen F; Dubois S; Fléjou JF
    Histopathology; 2000 Sep; 37(3):241-9. PubMed ID: 10971700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Demonstration of clonal heterogeneity in adenocarcinomas on Barrett's esophagus by flow cytometric study of cellular DNA content].
    Robaszkiewicz M; Volant A; Hardy E; Nousbaum JB; Calament G; Cauvin JM; Bail JP; Lozach P; Gouerou H
    Gastroenterol Clin Biol; 1992; 16(6-7):540-6. PubMed ID: 1526415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
    Chatelain D; Fléjou JF
    Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer.
    Matsumoto K; Irie A; Satoh T; Ishii J; Iwabuchi K; Iwamura M; Egawa S; Baba S
    Urology; 2007 Sep; 70(3):602-7. PubMed ID: 17688917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
    Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett's esophageal mucosa and in the gastric cardia.
    Kalish RJ; Clancy PE; Orringer MB; Appelman HD
    Gastroenterology; 1984 Mar; 86(3):461-7. PubMed ID: 6693012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. S100A2 overexpression is frequently observed in esophageal squamous cell carcinoma.
    Imazawa M; Hibi K; Fujitake S; Kodera Y; Ito K; Akiyama S; Nakao A
    Anticancer Res; 2005; 25(2B):1247-50. PubMed ID: 15865073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular genetic changes in metastatic primary Barrett's adenocarcinoma and related lymph node metastases: comparison with nonmetastatic Barrett's adenocarcinoma.
    Walch AK; Zitzelsberger HF; Bink K; Hutzler P; Bruch J; Braselmann H; Aubele MM; Mueller J; Stein H; Siewert JR; Höfler H; Werner M
    Mod Pathol; 2000 Jul; 13(7):814-24. PubMed ID: 10912943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions.
    Montgomery E; Mamelak AJ; Gibson M; Maitra A; Sheikh S; Amr SS; Yang S; Brock M; Forastiere A; Zhang S; Murphy KM; Berg KD
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):24-30. PubMed ID: 16540726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.
    Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV
    Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma.
    Hao Y; Triadafilopoulos G; Sahbaie P; Young HS; Omary MB; Lowe AW
    Gastroenterology; 2006 Sep; 131(3):925-33. PubMed ID: 16952561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
    Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.